News Headline Summary

Roche's Perjeta (ROG VX) significantly extends survival in people with HER2-positive metastatic breast cancer

Reaction details:

- In an immediate reaction company shares moved 0.16% higher from CHF 185.298 to CHF 185.601

Print 12:02, 10 Dec 2012 - SMI - Source: Newswires